Gilead Sciences (NASDAQ:GILD) CEO Sells $2,229,600.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 15,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the completion of the transaction, the chief executive officer owned 577,133 shares in the company, valued at $85,785,049.12. This trade represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, August 3rd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00.
• On Wednesday, July 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00.

Gilead Sciences Stock Down 0.2%

GILD opened at $150.99 on Friday. The firm’s 50 day simple moving average is $136.67 and its two-hundred day simple moving average is $136.52. The company has a market capitalization of $187.22 billion, a PE ratio of -56.55 and a beta of 0.33. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the previous year, the firm posted $2.01 EPS. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, equities analysts forecast that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GILD. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Wall Street Zen cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Finally, Morgan Stanley reduced their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research note on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV and oncology approvals broaden Gilead’s growth prospects. FDA approval of Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults on complex treatments, could strengthen the company’s HIV franchise. Separately, European approval of Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients expands Gilead’s oncology opportunity. Commercial uptake will determine the ultimate revenue impact. HIV and oncology approvals article
• Positive Sentiment: Analysts raised long-term earnings expectations. Zacks Research increased its Q1 2028 EPS estimate to $2.15, Q2 2028 to $2.31 and FY2028 to $9.66, while maintaining a “Strong Buy” rating. The revisions suggest improving confidence in Gilead’s future profitability. Gilead analyst estimates
• Positive Sentiment: An Arcus-backed cancer study reached completion. The milestone sets up a potentially important immuno-oncology catalyst, although investors will likely need to wait for efficacy and safety data before assigning significant value to the program. Arcus-backed cancer trial article
• Neutral Sentiment: Gilead continues to support income investors with a $0.82 quarterly dividend. The $3.28 annualized payout provides shareholder support, but the high payout relative to reported earnings makes future dividend growth dependent on sustained HIV cash flow and successful new-product launches. Gilead dividend article
• Neutral Sentiment: CEO Daniel O’Day sold $2.23 million of stock. The 15,000-share sale reduced his holdings by 2.53%, but it was completed under a pre-arranged Rule 10b5-1 plan, limiting its value as a bearish signal. SEC insider trading filing
• Negative Sentiment: Investors remain concerned about concentration and patent-expiration risk. Gilead’s dividend and cash generation depend heavily on its leading HIV franchise, particularly a blockbuster therapy facing a known patent expiration later in the next decade. The sharp decline in cell-therapy licensing deals also highlights uncertainty around diversification beyond HIV. Gilead dividend and patent risk article

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences in the fourth quarter worth about $25,000. Persistent Asset Partners Ltd purchased a new stake in Gilead Sciences during the second quarter valued at approximately $25,000. Kimelman & Baird LLC purchased a new stake in Gilead Sciences during the second quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the last quarter. Finally, Quattro Advisors LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $26,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.